Skip to main content
. 2012 Mar 31;61(11):1905–1916. doi: 10.1007/s00262-012-1249-x

Fig. 5.

Fig. 5

Antitumor effects of Ad-HER2-ECD on trastuzumab-resistant or low HER2-expresssing human cancer cells. Trastuzumab-resistant SKBR3 and BT474 breast cancer cells (a) and low HER2-expressing MKN1 and MKN28 gastric cancer cells (b) cultured as a monolayer were infected with Ad-HER2-ECD or control dl312 at an MOI of 20. The cell growth was determined by counting cell numbers each day after infection. The mean ± SD of three different wells is shown. *p < 0.05